NEW YORK, NY / ACCESSWIRE / January 28, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a ...

NEW YORK, NY / ACCESS Newswire / January 28, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about ...

The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as ...

Novo Nordisk (NVO) said its popular diabetes drug Ozempic, or semaglutide, has been approved for the treatment of patients with chronic kidney disease and diabetes. Read more here.

Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the ...

Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.

A new study led by Western researchers found frequent treatment with intranasal oxytocin – a hormone in the brain associated ...

Akero Therapeutics shares traded near their all-time high as the drugmaker reported positive results in a study of its treatment for liver disease.

Veru said on Monday its experimental drug, in combination with Novo Nordisk's weight-loss treatment Wegovy, helped preserve muscle in older patients with obesity, meeting the main goal of a mid-stage ...

Shares were mixed in thin Asian trading on Monday after U.S. stocks edged back from their all-time high. Oil prices fell and ...

Novo Nordisk’s NVO amycretin, which targets GLP-1 and amylin in one molecule, generated 24% placebo-adjusted weight loss in a ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...